Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

OKYO Pharma Ltd

OKYO ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$1.52

▲ +0.66%

Market Cap $79.77M · Vol 9.12K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$79.77M

Micro Cap

Div Yield

N/A

EPS Growth

+11.67%

YoY

RSI (14)

34.21

Momentum

Beta

0.39

vs Market

52W High

$3.20

52.50% below

52W Low

$1.35

12.59% above

Volume

9.12K

Avg 23.26K

P/B

5.18

Price-to-book

ROE

N/A

Return on equity

Free Float

68.95%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, OKYO Pharma Ltd (OKYO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OKYO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.01%

-3.80%

-5.59%

-13.14%

YTD

-26.57%

-42.42%

-7.88%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,833,166.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-72.54% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.18
P/FCF	N/A
EPS Growth	+11.67%
Outstanding Shares	52.48M

Technical Indicators

50-Day SMA	$1.56
200-Day SMA	$1.83
RSI (14)	34.21
Beta	0.39
52-Week High	$3.20
52-Week Low	$1.35

Volume Today	9.12K
Avg Daily Volume (30D)	23.26K
Relative Volume	0.39x
Volatility (10D)	40.32
Volatility (30D)	64.56
Free Float	68.95%

Analyst Consensus

BUY

Current Price $1.52

Mean Target $8.33

52W Low$1.35 52W High$3.20

Current

Target

$1.35 $3.20

Current Analyst target

+448.25% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG015TS36P0

ISINGG00BMFG5F62

CountryUnited Kingdom

Sub-IndustryBiopharmaceuticals

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.